Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.

× No keyword cloud information.

30 in total

1. Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data.

Authors: Oliver C Stoss; Andreas Scheel; Iris Nagelmeier; Hans-Ulrich Schildhaus; Thomas Henkel; Giuseppe Viale; Bharat Jasani; Michael Untch; Josef Rüschoff
Journal: Mod Pathol Date: 2015-09-25 Impact factor: 7.842

2. Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance.

Authors: Michael F Press; Michael A Gordon; Dennis J Slamon
Journal: J Clin Oncol Date: 2011-12-27 Impact factor: 44.544

3. Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer.

Authors: Anna Zaczek; Aleksandra Markiewicz; Anna Supernat; Natalia Bednarz-Knoll; Burkhardt Brandt; Barbara Seroczyńska; Jarosław Skokowski; Jolanta Szade; Piotr Czapiewski; Wojciech Biernat; Marzena Wełnicka-Jaśkiewicz; Jacek Jassem
Journal: Pathol Oncol Res Date: 2012-03-18 Impact factor: 3.201

4. TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer.

Authors: Ronan W Glynn; Sarah Mahon; Catherine Curran; Grace Callagy; Nicola Miller; Michael J Kerin
Journal: Oncologist Date: 2011-06-24

5. HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug.

Authors: Hui Ding; Pallavi R Gangalum; Anna Galstyan; Irving Fox; Rameshwar Patil; Paul Hubbard; Ramachandran Murali; Julia Y Ljubimova; Eggehard Holler
Journal: Nanomedicine Date: 2016-08-09 Impact factor: 5.307

6. Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.

Authors: Christian Schindlbeck; D Mayr; C Olivier; B Rack; V Engelstaedter; J Jueckstock; C Jenderek; U Andergassen; U Jeschke; K Friese
Journal: J Cancer Res Clin Oncol Date: 2010-01-06 Impact factor: 4.553

7. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.

Authors: Johan Staaf; Göran Jönsson; Markus Ringnér; Johan Vallon-Christersson; Dorthe Grabau; Adalgeir Arason; Haukur Gunnarsson; Bjarni A Agnarsson; Per-Olof Malmström; Oskar Th Johannsson; Niklas Loman; Rosa B Barkardottir; Ake Borg
Journal: Breast Cancer Res Date: 2010-05-06 Impact factor: 6.466

8. Genome profiling of ERBB2-amplified breast cancers.

Authors: Fabrice Sircoulomb; Ismahane Bekhouche; Pascal Finetti; José Adélaïde; Azza Ben Hamida; Julien Bonansea; Stéphane Raynaud; Charlène Innocenti; Emmanuelle Charafe-Jauffret; Carole Tarpin; Farhat Ben Ayed; Patrice Viens; Jocelyne Jacquemier; François Bertucci; Daniel Birnbaum; Max Chaffanet
Journal: BMC Cancer Date: 2010-10-08 Impact factor: 4.430

9. Aberrations of ERBB2 and TOP2A genes in breast cancer.

Authors: Kirsten Vang Nielsen; Sven Müller; Susanne Møller; Andreas Schønau; Eva Balslev; Ann S Knoop; Bent Ejlertsen
Journal: Mol Oncol Date: 2009-11-18 Impact factor: 6.603

Review 10. New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin.

Authors: Iain Rj Macpherson; Tr Jeffry Evans
Journal: Breast Cancer (Dove Med Press) Date: 2009-08-31